We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+23.3%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.61B
AUM Growth
+$111M
Cap. Flow
-$113M
Cap. Flow %
-6.99%
Top 10 Hldgs %
70.44%
Holding
46
New
2
Increased
1
Reduced
5
Closed
2

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$17.8M
2
RGLS
Regulus Therapeutics
RGLS
+$7.37M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$1.08M

Top Sells

Rank Stock Value
1
MYND
Mynd.ai
MYND
+$98.8M
2
GERN icon
Geron
GERN
+$22.4M
3
SGMT icon
Sagimet Biosciences
SGMT
+$13.3M
4
CBIO
Crescent Biopharma
CBIO
+$2.78M
5
ACRV icon
Acrivon Therapeutics
ACRV
+$1.29M

Sector Composition

Rank Sector Weight
1 Healthcare 86.79%
2 Consumer Staples 6.72%
3 Technology 3.98%
4 Industrials 2.07%
5 Communication Services 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
1
DELISTED
Arcellx
ACLX
$260M 16.17%
3,745,262
– –
CRSP icon
2
CRISPR Therapeutics
CRSP
$4.69B
$180M 11.2%
1,587,854
– –
RYTM icon
3
Rhythm Pharmaceuticals
RYTM
$7.31B
$126M 7.83%
2,909,956
– –
SVRA icon
4
Savara
SVRA
$1.08B
$122M 7.56%
24,471,264
– –
COUR icon
5
Coursera
COUR
$1.77B
$108M 6.72%
12,867,769
– –
KRRO icon
6
Korro Bio
KRRO
$145M
$96.6M 5.99%
1,072,936
– –
VRNA
7
DELISTED
Verona Pharma
VRNA
$89.9M 5.58%
5,108,563
– –
GLUE icon
8
Monte Rosa Therapeutics
GLUE
$1.82B
$54.2M 3.37%
7,692,298
– –
NN icon
9
NextNav
NN
$1.79B
$53.9M 3.34%
8,189,156
– –
CVRX icon
10
CVRx
CVRX
$131M
$43.2M 2.68%
2,370,542
– –
GERN icon
11
Geron
GERN
$898M
$42.2M 2.62%
12,776,409
-10,000,000
-44% -$22.4M
TRVI icon
12
Trevi Therapeutics
TRVI
$2.57B
$39.2M 2.44%
11,370,376
– –
NKTX icon
13
Nkarta
NKTX
$152M
$38.6M 2.39%
3,568,781
– –
CELC icon
14
Celcuity
CELC
$4.06B
$27M 1.68%
1,250,001
– –
ADAP
15
DELISTED
Adaptimmune Therapeutics
ADAP
$27M 1.68%
17,079,778
– –
BDTX icon
16
Black Diamond Therapeutics
BDTX
$95.1M
$22.6M 1.4%
4,448,757
– –
XFOR icon
17
X4 Pharmaceuticals
XFOR
$377M
$20.8M 1.29%
499,560
– –
PHAT icon
18
Phathom Pharmaceuticals
PHAT
$928M
$20.8M 1.29%
1,960,169
– –
ORIC icon
19
Oric Pharmaceuticals
ORIC
$1.17B
$20.6M 1.28%
+1,500,000
New +$17.8M
ZFOX
20
DELISTED
ZeroFox Holdings, Inc. Common Stock
ZFOX
$20.2M 1.26%
18,068,513
– –
AUPH icon
21
Aurinia Pharmaceuticals
AUPH
$1.95B
$19.9M 1.23%
3,969,834
– –
GOSS icon
22
Gossamer Bio
GOSS
$101M
$18.7M 1.16%
15,838,009
– –
INZY
23
DELISTED
Inozyme Pharma
INZY
$18.7M 1.16%
2,437,689
– –
RGLS
24
DELISTED
Regulus Therapeutics
RGLS
$18.6M 1.16%
6,467,802
+4,522,223
+232% +$7.37M
NEUE
25
DELISTED
NeueHealth
NEUE
$17.7M 1.1%
2,726,917
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q1 2024 Portfolio in Review

As of Q1 2024, NEA Management Company held 46 positions worth $1.61B, up 7.4% from $1.5B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

NEA Management Company withdrew a net $113M in Q1 2024, closing 2 positions and reducing 5 holdings. Its most notable exit was Acrivon Therapeutics, an estimated $1.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 78% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, NEA Management Company opened a new position in Oric Pharmaceuticals worth $20.6M.

  • NEA Management Company's largest Q1 2024 buy was Oric Pharmaceuticals: 1,500,000 shares worth $20.6M.
  • NEA Management Company added most to Regulus Therapeutics in Q1 2024, an estimated $7.37M increase.
  • NEA Management Company's biggest Q1 2024 reduction was Mynd.ai, cutting an estimated $98.8M.
  • NEA Management Company fully exited Acrivon Therapeutics in Q1 2024, selling an estimated $1.29M.
  • NEA Management Company's ten largest holdings make up 70% of its $1.61B portfolio in Q1 2024.
  • NEA Management Company opened 2 new positions and closed 2 in Q1 2024.
  • NEA Management Company's portfolio value rose 7.4% quarter-over-quarter to $1.61B.

Based on NEA Management Company's 13F filing for Q1 2024, filed 15 May 2024.